Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Exclusive: Pfizer begins to export U.S.-made COVID-19 shots, first doses sent to Mexico

Published 04/29/2021, 09:27 PM
Updated 04/29/2021, 09:35 PM
© Reuters. A person walks past a Pfizer logo in New York City

By Carl O'Donnell

(Reuters) - Pfizer Inc (NYSE:PFE)'s shipment of COVID-19 vaccine to Mexico this week includes doses made in its U.S. plant, the first of what are expected to be ongoing exports of its shots from the United States, a source familiar with the matter told Reuters on Thursday.

The vaccine shipment, produced at Pfizer's Kalamazoo, Michigan plant, marks the first time the drugmaker has delivered abroad from U.S facilities after a Trump-era restriction on dose exports expired at the end of March, the source said.

The U.S. government has been under mounting pressure in recent weeks to provide surplus vaccines to other nations desperately in need as it makes swift progress vaccinating its own residents. Many countries where the virus is still rampant are struggling to acquire vaccine supplies to help tame the pandemic.

Wealthy governments have been trying to stock up on COVID-19 shots from Pfizer and Moderna (NASDAQ:MRNA) Inc because of their extremely high efficacy and after safety concerns and production problems temporarily sidelined vaccines from AstraZeneca (NASDAQ:AZN) Plc and Johnson & Johnson (NYSE:JNJ).

Pfizer has shipped more than 10 million doses to Mexico so far, becoming its largest supplier of COVID-19 vaccine.

Pfizer and German partner BioNTech SE (NASDAQ:BNTX) have been supplying other countries with doses from its main European production plant in Belgium.

Mexico’s health ministry said it is receiving 2 million doses from Pfizer this week. It has received more than a million doses from Belgium since Wednesday and expects around another million this week. Reuters could not confirm if all the remaining Pfizer doses would come from Michigan.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Pfizer will use extra capacity in its U.S. facilities to deliver shots abroad while continuing to meet its commitment to supply the United States, the source said, adding that the drugmaker will also make shipments from Belgium.

Pfizer has said it will be making up to 25 million shots each week in the United States by mid-year, which is more than it needs to meet its commitment to deliver 300 million doses to the United States by the end of July.

The company expects to produce as many as 2.5 billion vaccine doses in 2021 and already has agreements to supply more than a billion to governments around the world.

A deal Pfizer signed with the White House last year had barred it from shipping doses made in the United States to other countries until after March 31, according to the source and a U.S. official, who declined to be named because he was not authorized to speak to the press.

The U.S. vaccination campaign has been among the quickest and most successful in the world, with nearly 240 million shots administered to more than 140 million residents so far, according to federal data updated on Thursday.

The White House on Monday said it would export up to 60 million doses of AstraZeneca's COVID-19 vaccine that have been made in a U.S. facility to countries in need.

Officials said on Monday the United States no longer anticipates needing the AstraZeneca vaccine to meet its goal of having enough shots for all Americans by summer.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The U.S. government on Sunday said it will immediately ship raw materials for COVID-19 vaccines, medical equipment and protective gear to India, which has become the latest epicenter of the pandemic with its health system on the brink of collapse. It has not yet promised finished vaccine shipments to India.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.